Sponsors (19)
The bill extends orphan-drug protections to delay price negotiations—trading near-term savings for taxpayers and lower drug costs for many patients in exchange for preserving manufacturer revenues and incentives to develop treatments for rare diseases.
Manufacturers and investors in specialty drugs: drugs that had orphan status keep longer exclusion from the Drug Price Negotiation Program, preserving market exclusivity and near-term revenue streams.
Patients with rare diseases: strengthened orphan protections help maintain incentives for R&D into rare conditions, which could improve future availability of therapies for small patient populations.
Patients currently treated for specific rare-disease indications and their providers: exclusion of more orphan-protected time delays price negotiations for those indications, which in practice keeps current pricing and market arrangements stable for a longer period.
Medicare and Medicaid beneficiaries and U.S. taxpayers: delaying inclusion of orphan-designated drugs in the Drug Price Negotiation Program reduces near-term federal savings and increases program costs.
Patients who would benefit from negotiated price reductions (including many with chronic or costly conditions and Medicare enrollees): may face higher drug prices for longer because orphan-status drugs avoid earlier negotiation.
Insurers, hospitals, and employer-sponsored plans: extended periods without negotiated lower prices for affected drugs could raise insurer and hospital spending, potentially increasing premiums and health-care costs.
Based on analysis of 2 sections of legislative text.
Treats orphan-drug designation periods as excluded from the Drug Price Negotiation Program's elapsed-time calculation and broadens the orphan definition to include products for one or more rare diseases.
Amends the federal drug-price negotiation rules to treat any time a drug held orphan-drug status as excluded from the program’s "elapsed-time" calculation, and expands the orphan definition so products can qualify if they treat one or more rare diseases or conditions. The change directs the HHS Secretary to apply this exclusion when determining a drug’s age for negotiation eligibility, which can delay or prevent some drugs from entering negotiated-price lists.
Introduced February 4, 2025 by John Joyce · Last progress February 4, 2025